Wendy's has rejected a $1.4 billion takeover offer from an investor group led by Trian, opting instead for a one-year poison pill (a shareholder rights plan that dilutes any buyer who crosses an ownership threshold) to keep the bidder at bay.

The offer came in at $7.35 a share in cash. The group behind it includes Trian, BlueFive Capital, Sixth Street Partners and Flynn Group, one of Wendy's largest franchisees, according to CNBC.

Why did the board say no?

The math explains the standoff. Wendy's stock has gained 37% over the past 11 trading sessions and now sits near $8 — without posting a single losing session in that stretch, per MarketWatch. That rally has nearly erased the stock's decline for this year, but the shares still trade far below the highs north of $20 they reached in the early 2020s. The stock has shed roughly 60% of its value across three years, and CNBC reports the takeover offer itself gave the shares their lift.

The board had prepared for this moment. In February, after Trian made a regulatory filing signaling its intentions, Wendy's formed a committee of independent directors to assess any bid from the firm, according to CNBC. That committee reached a clear verdict: the offer "substantially undervalues" Wendy's and overlooks the benefits the chain could see from its turnaround strategy.

Art Winkleblack, who chairs Wendy's board and sits on the independent committee, put the reasoning plainly in a statement. "Our confidence rests firmly in [CEO] Bob Wright's proven track record of seasoned industry leadership, including restaurant business turnarounds," he said, according to CNBC.

Trian declined to comment on the decision.

How is Wendy's defending itself?

The poison pill went into effect on Nov. 4 and runs for one year, according to CNBC. It's a classic anti-takeover device. If a hostile buyer accumulates shares past a set limit, existing shareholders get the right to buy stock at a discount, making the acquisition punishingly expensive.

One detail drove the timing. The Trian-led group rebuffed a proposal from Wendy's to sign a standstill agreement (a pact freezing further stock purchases), and that refusal contributed directly to the decision to adopt the pill, CNBC reported.

The market's first read was mild. Wendy's stock dipped by under 1% in early trading on Nov. 5.

What's the history here?

This isn't a hostile raid by outsiders. It's a family dispute of sorts. Nelson Peltz spent 17 years on Wendy's board before the company named him chairman emeritus in 2024, according to CNBC. Trian's influence doesn't end there: Trian executive Peter May and Peltz's son, Bradley Peltz, both remain on the board.

That history cuts both ways. It gives the Trian group unusual insight into the company it's trying to buy. But it also means Wendy's leadership knows exactly how the bidder operates, and the independent committee structure — set up back in February — gave the board a firewall to evaluate any offer without the insiders in the room.

What happens next?

The rejection leaves three live threads:

• The poison pill runs for roughly a year, until November 2026, blocking any hostile accumulation.
• The Trian group could return with a higher bid, though it refused to limit its stock buying when asked.
• Wendy's management, led by CEO Bob Wright, now has to show the turnaround strategy can deliver more than $7.35 a share's worth of value.

The stock's 37% surge shows investors think this story isn't over. A bidder that walks away rarely walks away permanently — and with the shares still under $8 against highs above $20, the gap between what Trian offered and what the board believes Wendy's is worth remains the whole game.